Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Adv Ther ; 37(5): 2169-2183, 2020 05.
Artigo em Inglês | MEDLINE | ID: mdl-32200533

RESUMO

INTRODUCTION: Omega-3 fatty acid ethyl esters (omega-3), an eicosapentaenoic acid and docosahexaenoic acid preparation (Lotriga®, Takeda Pharmaceutical Company Limited), are approved in Japan to treat triglyceridemia. We investigated the effects of omega-3 on vascular endothelial function, measured by flow-mediated dilation (FMD). METHODS: Patients with dyslipidemia receiving 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors were randomized 1:1 to receive omega-3 at 2 g (QD) or 4 g (2 g BID) for 8 weeks. The primary end point was the change from baseline of fasting  %FMD in each treatment group. Secondary end points included the 4-h postprandial  %FMD and 4-h postprandial triglyceride (TG) level. RESULTS: Thirty-seven patients were randomized to receive omega-3 at 2 g (n = 18) or 4 g (n = 19). Mean fasting %FMD did not increase from baseline to week 8 in the 2-g group (- 1.2%) or 4-g group (- 1.3%). Mean 4-h postprandial %FMD did not change from baseline to week 8 in the 2-g group (0.0%), but increased in the 4-g group (1.0%). Mean 4-h postprandial TG level decreased by 34.7 mg/dl from baseline over week 8 in the 2-g group, with a significantly larger decrease in the 4-g group of 75.9 mg/dl (p < 0.001). No new safety concerns were identified. CONCLUSIONS: Fasting %FMD did not improve after 8 weeks of omega-3 treatment at 2 g or 4 g. After 8 weeks, 4-h postprandial TG levels showed improvement at both doses, with a greater reduction in the 4-g group. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT02824432.


Assuntos
Endotélio Vascular/efeitos dos fármacos , Jejum/sangue , Ácidos Graxos Ômega-3/administração & dosagem , Ácidos Graxos Ômega-3/farmacologia , Hiperlipidemias/sangue , Hiperlipidemias/dietoterapia , Período Pós-Prandial/efeitos dos fármacos , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Japão , Masculino , Pessoa de Meia-Idade , Distribuição Aleatória
2.
Cardiovasc Interv Ther ; 33(2): 116-124, 2018 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-28110424

RESUMO

We investigated the effects of caffeine intake on fractional flow reserve (FFR) values measured using intravenous adenosine triphosphate (ATP) before cardiac catheterization. Caffeine is a competitive antagonist for adenosine receptors; however, it is unclear whether this antagonism affects FFR values. Patients were evenly randomized into 2 groups preceding the FFR study. In the caffeine group (n = 15), participants were given coffee containing 222 mg of caffeine 2 h before the catheterization. In the non-caffeine group (n = 15), participants were instructed not to take any caffeine-containing drinks or foods for at least 12 h before the catheterization. FFR was performed in patients with more than intermediate coronary stenosis using the intravenous infusion of ATP at 140 µg/kg/min (normal dose) and 170 µg/kg/min (high dose), and the intracoronary infusion of papaverine. FFR was followed for 30 s after maximal hyperemia. In the non-caffeine group, the FFR values measured with ATP infusion were not significantly different from those measured with papaverine infusion. However, in the caffeine group, the FFR values were significantly higher after ATP infusion than after papaverine infusion (P = 0.002 and P = 0.007, at normal and high dose ATP vs. papaverine, respectively). FFR values with ATP infusion were significantly increased 30 s after maximal hyperemia (P = 0.001 and P < 0.001 for normal and high dose ATP, respectively). The stability of the FFR values using papaverine showed no significant difference between the 2 groups. Caffeine intake before the FFR study affected FFR values and their stability. These effects could not be reversed by an increased ATP dose.


Assuntos
Trifosfato de Adenosina/farmacologia , Angina Pectoris/fisiopatologia , Cafeína/farmacologia , Estenose Coronária/fisiopatologia , Reserva Fracionada de Fluxo Miocárdico/efeitos dos fármacos , Neurotransmissores/farmacologia , Trifosfato de Adenosina/administração & dosagem , Trifosfato de Adenosina/antagonistas & inibidores , Idoso , Angina Pectoris/etiologia , Cateterismo Cardíaco , Café , Angiografia Coronária , Estenose Coronária/diagnóstico por imagem , Feminino , Reserva Fracionada de Fluxo Miocárdico/fisiologia , Hemodinâmica , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Neurotransmissores/administração & dosagem , Neurotransmissores/antagonistas & inibidores , Papaverina/administração & dosagem , Papaverina/farmacologia , Estudos Prospectivos , Vasodilatadores/administração & dosagem , Vasodilatadores/antagonistas & inibidores , Vasodilatadores/farmacologia
3.
Int J Cardiol ; 158(2): 246-52, 2012 Jul 12.
Artigo em Inglês | MEDLINE | ID: mdl-21342709

RESUMO

BACKGROUND: As an initial management strategy for stable ischemic heart disease (IHD), coronary revascularization therapy is thought to be equal to optimal medical therapy alone regarding prognosis. METHODS: Whether or not the effects of revascularization on the prognosis of patients with stable IHD are associated with the amount of ischemic myocardium detected by nuclear stress imaging was evaluated. This retrospective study analyzed data from 4629 patients with suspected or known IHD who underwent gated stress myocardial-perfusion SPECT at 117 hospitals in Japan. The follow-up periods were three years and the combined endpoints consisted of cardiac death, nonfatal myocardial infarction, and congestive heart failure requiring hospitalization. After matching propensity scores between patients who underwent early revascularization and those who did not (n=316 per group), we compared cardiac event rates in relation to the amount of ischemic myocardium. RESULTS: Cardiac event rates did not significantly differ between patients who underwent early revascularization and those who did not (5.4% vs. 6.4%). Among patients with ≤ 5%, 6-10%, and >10% ischemic myocardium, cardiac event rates were 8%, 3% and 0% respectively, who underwent early revascularization compared with 4.5%, 6.1%, and 12.3%, respectively, among those who did not. Cardiac event rates were significantly lower among patients with >10% ischemic myocardium who underwent early revascularization compared with those who did not (0% vs. 12.3%, p=0.0062). CONCLUSIONS: Coronary revascularization for stable IHD does not decrease major cardiac events in all patients but might do in patients with moderate to severe ischemia.


Assuntos
Isquemia Miocárdica/diagnóstico por imagem , Isquemia Miocárdica/cirurgia , Revascularização Miocárdica/tendências , Índice de Gravidade de Doença , Idoso , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Tomografia Computadorizada de Emissão de Fóton Único/tendências , Resultado do Tratamento
4.
Atherosclerosis ; 217(2): 433-6, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21536287

RESUMO

OBJECTIVE: We examined the relationship among the serum omega-3 and omega-6 fatty acid (O3FA and O6FA) levels, serum C-reactive protein (CRP) levels, and arterial stiffness/wave reflection (AS/WR) in healthy Japanese men. METHODS: In 2206 Japanese healthy men, parameters related to the AS/WR (i.e., brachial-ankle pulse wave velocity and radial arterial pulse wave analysis) were measured. RESULTS: No significant inverse relationships were observed between the serum O3FA levels and the AS/WR-related parameters. Adjusted values of the AS/WR-related parameters and serum CRP levels were higher in the subjects with serum O6FA levels in the highest tertile than in those with serum O6FA levels in the lowest tertile. CONCLUSIONS: In healthy Japanese men with known high dietary intakes of O3FAs, the serum O3FA levels may not reflect the pathophysiological abnormalities related to AS/WR. Increased serum O6FA levels appeared to be independently associated with the unfavorable conditions related to AS/WR and inflammation.


Assuntos
Povo Asiático , Artéria Braquial/fisiopatologia , Proteína C-Reativa/análise , Ácidos Graxos Ômega-3/sangue , Ácidos Graxos Ômega-6/sangue , Inflamação , Doença Arterial Periférica , Fluxo Pulsátil , Artéria Radial/fisiopatologia , Adulto , Índice Tornozelo-Braço , Povo Asiático/estatística & dados numéricos , Biomarcadores/sangue , Velocidade do Fluxo Sanguíneo , Complacência (Medida de Distensibilidade) , Humanos , Inflamação/sangue , Inflamação/etnologia , Inflamação/imunologia , Inflamação/fisiopatologia , Japão , Masculino , Pessoa de Meia-Idade , Doença Arterial Periférica/sangue , Doença Arterial Periférica/etnologia , Doença Arterial Periférica/imunologia , Doença Arterial Periférica/fisiopatologia
5.
Hypertens Res ; 28(8): 651-5, 2005 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16392769

RESUMO

The present study was conducted to examine the effect of eicosapentaenoic acid supplements on pulse wave velocity (PWV) in patients with dyslipidemia as a prospective open-labeled study. Eicosapentaenoic acid supplements (1,800 mg/day) were prescribed to 40 patients, and diet therapy in consultation with a nutritionist was conducted in 44 patients as a control group. These interventions were continued for 12 months, and PWV and blood examinations were performed at the start and end of these interventions. PWV increased in the control group but not in the eicosapentaenoic acid group. After adjustment for age, gender, the initial PWV, and the changes in mean blood pressure during the study period, a general linear model univariate analysis post hoc comparison demonstrated that the change in PWV during the period of study was significantly larger in the control group (42 +/- 20 cm/s) than in the eicosapentaenoic acid group (-9 +/- 19 cm/s) (p<0.05). Thus, this preliminary study suggested that eicosapentaenoic acid supplements attenuate age-related increases in arterial stiffness in patients with dyslipidemia. A further study with a larger number of subjects is proposed to confirm this beneficial effect of eicosapentaenoic acid supplements on arterial stiffness.


Assuntos
Envelhecimento/fisiologia , Artérias/fisiopatologia , Arteriosclerose/fisiopatologia , Suplementos Nutricionais , Dislipidemias/tratamento farmacológico , Ácido Eicosapentaenoico/uso terapêutico , Idoso , Artérias/efeitos dos fármacos , Arteriosclerose/prevenção & controle , Pressão Sanguínea/efeitos dos fármacos , Pressão Sanguínea/fisiologia , Artéria Braquial/fisiologia , Interpretação Estatística de Dados , Dislipidemias/dietoterapia , Dislipidemias/fisiopatologia , Ácido Eicosapentaenoico/administração & dosagem , Ácido Eicosapentaenoico/farmacologia , Elasticidade/efeitos dos fármacos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pulso Arterial , Análise de Regressão , Resistência Vascular/efeitos dos fármacos , Resistência Vascular/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA